FGFR2 testing in cholangiocarcinoma: translating molecular studies into clinical practice

被引：5

作者：

Angerilli, Valentina ^{[1
]}

Fornaro, Lorenzo ^{[2
]}

Pepe, Francesco ^{[3
]}

Rossi, Silvia Maria ^{[4
,5
]}

Perrone, Giuseppe ^{[4
,5
]}

Malapelle, Umberto ^{[3
]}

Fassan, Matteo ^{[1
,6
]}

机构：

[1] Univ Padua, Dept Med DIMED, Surg Pathol Unit, Padua, PD, Italy

[2] Azienda Osped Univ Pisana, Med Oncol, Pisa, PI, Italy

[3] Univ Naples Federico II, Dept Publ Hlth, Naples, Italy

[4] Univ Campus Bio Med Roma, Dept Med & Surg, Res Unit Anat Pathol, Rome, Italy

[5] Fondazione Policlin Univ Campus Bio Med, Anat Pathol Operat Res Unit, Rome, Italy

[6] IOV IRCCS, Veneto Inst Oncol, Padua, Italy

来源：

PATHOLOGICA | 2023年 / 115卷 / 02期

关键词：

cholangiocarcinoma; precision medicine; FGFR2; biomarkers; OPEN-LABEL; METASTATIC CHOLANGIOCARCINOMA; FORMALIN FIXATION; SINGLE-ARM; RNA; MULTICENTER; FUSIONS; CHEMOTHERAPY; BGJ398; TISSUE;

D O I：

10.32074/1591-951X-859

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

Cholangiocarcinoma (CCA) is a heterogeneous group of neoplasms burdened by a dismal prognosis. Several studies have investigated the genomic profile of CCA and identi!ed numerous druggable genetic alterations, including FGFR2 fusions/rearrangements. Approximately 5-7% of CCAs and 10-20% of intrahepatic iCCAs harbor FGFR2 fusions. With the recent advent of FGFR-targeting therapies into clinical practice, a standardization of molecular testing for FGFR2 alterations in CCA will be necessary. In this review, we describe the technical aspects and challenges related to FGFR2 testing in routine practice, focusing on the comparison between Next-Generation Sequencing (NGS) and FISH assays, the best timing to perform the test, and on the role of liquid biopsy.

引用

页码：71 / 82

页数：12

共 50 条

[31] Clinical impact of FGFR inhibitors on FGFR2 positive pancreatic cancer
Stein, Leah
Reeser, Julie W.
Wing, Michele R.
Murugesan, Karthikeyan
Paruchuri, Anoosha
Risch, Zachary
Samorodnitsky, Eric
Hoskins, Emily L.
Smith, Amy
Dao, Thuy
Babcook, Melissa
Imam, Muhammad
Freud, Aharon
Roychowdhury, Sameek
CANCER RESEARCH, 2023, 83 (07)
[32] FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations
Pedro Luiz Serrano Uson Junior
Thomas T. DeLeon
James M. Bogenberger
Rish K. Pai
Heidi E. Kosiorek
Jun Yin
Daniel H. Ahn
Mohammad Bassam Sonbol
Tanios Bekaii-Saab
Aaron S. Mansfield
Kenneth Buetow
Gregory J. Gores
Rory Smoot
George Vasmatzis
Benjamin R. Kipp
Amit Mahipal
Alexander T. Baker
Hani Babiker
Oumar Barro
Chelsae Dumbauld
Yumei Zhou
Faaiq N. Aslam
Michael Barrett
Bertram Jacobs
Nathalie Meurice
Mansi Arora
Joachim Petit
Natalie Elliott
Bolni Nagalo
Marcela A. Salomao
Mitesh J. Borad
Digestive Diseases and Sciences, 2022, 67 : 3797 - 3805
[33] FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations
Uson, Pedro Luiz Serrano, Jr.
DeLeon, Thomas T.
Bogenberger, James M.
Pai, Rish K.
Kosiorek, Heidi E.
Yin, Jun
Ahn, Daniel H.
Sonbol, Mohammad Bassam
Bekaii-Saab, Tanios
Mansfield, Aaron S.
Buetow, Kenneth
Gores, Gregory J.
Smoot, Rory
Vasmatzis, George
Kipp, Benjamin R.
Mahipal, Amit
Baker, Alexander T.
Babiker, Hani
Barro, Oumar
Dumbauld, Chelsae
Zhou, Yumei
Aslam, Faaiq N.
Barrett, Michael
Jacobs, Bertram
Meurice, Nathalie
Arora, Mansi
Petit, Joachim
Elliott, Natalie
Nagalo, Bolni
Salomao, Marcela A.
Borad, Mitesh J.
DIGESTIVE DISEASES AND SCIENCES, 2022, 67 (08) : 3797 - 3805
[34] FGFR2-BICC1: A Subtype Of FGFR2 Oncogenic Fusion Variant In Cholangiocarcinoma And The Response To Sorafenib
Ying, Xihui
Tu, Jianfei
Wang, Wenxian
Li, Xingliang
Xu, Chunwei
Ji, Jiansong
ONCOTARGETS AND THERAPY, 2019, 12 : 9303 - 9307
[35] Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies
Giovanni Brandi
Valeria Relli
Marzia Deserti
Andrea Palloni
Valentina Indio
Annalisa Astolfi
Salvatore Serravalle
Alessandro Mattiaccio
Francesco Vasuri
Deborah Malvi
Chiara Deiana
Maria Abbondanza Pantaleo
Matteo Cescon
Alessandro Rizzo
Masaru Katoh
Simona Tavolari
Scientific Reports, 14
[36] Activated FGFR2 signalling as a biomarker for selection of intrahepatic cholangiocarcinoma patients candidate to FGFR targeted therapies
Brandi, Giovanni
Relli, Valeria
Deserti, Marzia
Palloni, Andrea
Indio, Valentina
Astolfi, Annalisa
Serravalle, Salvatore
Mattiaccio, Alessandro
Vasuri, Francesco
Malvi, Deborah
Deiana, Chiara
Pantaleo, Maria Abbondanza
Cescon, Matteo
Rizzo, Alessandro
Katoh, Masaru
Tavolari, Simona
SCIENTIFIC REPORTS, 2024, 14 (01)
[37] Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 Alterations
Varghese, Anna M.
Patel, Juber
Janjigian, Yelena Y.
Meng, Fanli
Selcuklu, S. Duygu
Iyer, Gopakumar
Houck-Loomis, Brian
Harding, James J.
O'Reilly, Eileen M.
Abou-Alfa, Ghassan K.
Lowery, Maeve A.
Berger, Michael F.
JCO PRECISION ONCOLOGY, 2021, 5 : 44 - 50
[38] FGFR2 Alterations in Primary Intrahepatic Cholangiocarcinoma: Driving New Routes for Therapy
Mirchia, Kanish
Gay, Laurie
Elvin, Julia
Vergilio, Jo-Anne
Killian, J. Keith
Nhu Ngo
Ramkissoon, Shakti
Severson, Eric
Hemmerich, Amanda
Chung, Jon
Ali, Siraj
Schrock, Alexa
Reddy, Venkataprasanth
Miller, Vincent
Corona, Robert
Ross, Jeffrey
MODERN PATHOLOGY, 2019, 32
[39] FGFR2 Alterations in Primary Intrahepatic Cholangiocarcinoma: Driving New Routes for Therapy
Mirchia, Kanish
Gay, Laurie
Elvin, Julia
Vergilio, Jo-Anne
Killian, J. Keith
Nhu Ngo
Ramkissoon, Shakti
Severson, Eric
Hemmerich, Amanda
Chung, Jon
Ali, Siraj
Schrock, Alexa
Reddy, Venkataprasanth
Miller, Vincent
Corona, Robert
Ross, Jeffrey
LABORATORY INVESTIGATION, 2019, 99
[40] Regulation of the Molecular Brake Region in FGFR2 Kinase
Karp, Jerome M.
Cowburn, David
BIOPHYSICAL JOURNAL, 2015, 108 (02) : 530A - 530A

← 1 2 3 4 5 →